# A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

> **NCT01002092** · PHASE2 · UNKNOWN · sponsor: **Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT01002092
- **Lead sponsor:** Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002092, "A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01002092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*